Alzinova works with the development of Alzheimer's drugs and has developed a unique approach to counteract the disease that can have a major impact on the care and prevention of Alzheimer's disease. The Company's goal is to take its drug candidates through clinical studies and to the market and become a market leader in the treatment of the disease. Alzinova is now taking another important step in this direction by recruiting Kirsten Harting as Chief Medical Officer (CMO).

Kirsten Harting has a medical degree, an executive MBA from Copenhagen Business School and more than 30 years of experience in medicine, clinical studies and drug development as well as business development and bringing products to market from Lundbeck, Pfizer, ALK and Novo Nordisk, among others. Kirsten comes from the role as Senior Medical Director at Cytoki Pharma and will start her position as CMO at Alzinova on August 14.

"We are very pleased to welcome Kirsten Harting to the Alzinova team as our new Chief Medical Officer. Her extensive knowledge and expertise in medicine, clinical studies and business development, combined with her experience in the pharmaceutical industry, is incredibly valuable for Alzinova's future development", says Kristina Torfgård, CEO of Alzinova.

"I am really looking forward to joining Alzinova. The Company already has an opportunity to take a strong position in the market, and I believe that Alzinova's drug candidates can have a significant impact on patients, relatives and healthcare professionals. My role at Alzinova will focus on being the patient's voice in the Company's management team and ensuring that we conduct clinical studies in the best possible way and thus get great results and eventually see the drug on the market", says Kirsten Harding.